๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4396 Illinois 2477 Georgia 2346 Arizona 2230
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Colorado

2067 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3
160
Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Mississippi
2023-08-08
Active, closed
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
NCT05972629Phenylketonuria
Sanofi
Phase 1/2
32
California, Colorado, Florida, Ohio, Pennsylvania, South Carolina, Texas
2023-08-07
Recruiting
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511cGVHD
Incyte Corporation
Observational
1,500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2023-08-01
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
NCT05762107Type 1 Diabetes Mellitus With Hypoglycemia
Zucara Therapeutics Inc.
Phase 2
186
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-28
Recruiting
AMT-116 in Patients With Advanced Solid Tumors
NCT05725291Advanced Solid Tumor
Multitude Therapeutics Inc.
Phase 1
80
Colorado, Texas
2023-07-25
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-25
Active, closed
Cemented vs Cementless Persona Keel RCT
NCT05630053Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis
Zimmer Biomet
Not applicable
300
Colorado, Illinois, Maryland, Oregon, Pennsylvania, Virginia
2023-07-25
Active, closed
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
NCT05757713Diabetes Mellitus, Type 1
Sanofi
Phase 4
20
California, Colorado, Connecticut, Georgia, Indiana, New York, Pennsylvania, South Dakota
2023-07-25
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234Relapsed/Refractory Multiple Myeloma
AstraZeneca
Phase 1/2
232
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-07-20
Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT05735184Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1
Kura Oncology, Inc.
Phase 1
420
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2023-07-18
Active, closed
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430Hypertension
Mineralys Therapeutics Inc.
Phase 3
1,076
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-07-14
Active, closed
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
Taiho Oncology, Inc.
Phase 2
53
California, Colorado, Florida, Michigan, New Jersey, New York, Ohio, Pennsylvania
2023-07-13
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-11
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Alabama, California, Colorado, Florida, Illinois, Indiana, Iowa, Minnesota
2023-07-06
Active, closed
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763Hemophilia A
Sanofi
Observational
200
Arizona, California, Colorado, Florida, Illinois, Indiana, Iowa, Massachusetts
2023-06-30
Active, closed
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Observational
760
Colorado, Florida, Georgia, Kentucky, Michigan, Minnesota, Mississippi, New Mexico
2023-06-28
Recruiting
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
NCT05785754Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
Phase 1
320
Alabama, Arizona, Colorado, Connecticut, Florida, Maryland, Massachusetts, Minnesota
2023-06-28
Active, closed
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Merck Sharp & Dohme LLC
Phase 1/2
390
California, Colorado, Georgia, Indiana, Massachusetts, Missouri, New York, North Carolina
2023-06-23
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
Bristol-Myers Squibb
Phase 3
1,230
Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2023-06-22
By invitation
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
NCT05929807Achondroplasia
Ascendis Pharma Growth Disorders A/S
Phase 2/3
140
Arkansas, Colorado, Delaware, Minnesota, Montana, New York, Texas, Wisconsin
2023-06-21
Active, closed
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930Recurrent Wheezing, Wheezing Lower Respiratory Illness
OM Pharma SA
Phase 2
296
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Kentucky
2023-06-20
Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc
Phase 1
60
Colorado, Florida, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington
2023-06-20
Active, closed
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05768854Osteogenesis Imperfecta
Ultragenyx Pharmaceutical Inc
Phase 3
69
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois
2023-06-14
Recruiting
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963Relapsing Multiple Sclerosis
TG Therapeutics, Inc.
Phase 3
800
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-06-13
Active, closed
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
NCT05898620Rett Syndrome
Neurogene Inc.
Phase 3
33
Alabama, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York
2023-06-13
Active, closed
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Tango Therapeutics, Inc.
Phase 1/2
126
California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-06-12
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
AbbVie
Phase 1
135
Arizona, California, Colorado, Illinois, Massachusetts, New Jersey, New York, Ohio
2023-06-09
Recruiting
Study of ALTO-300 in MDD
NCT05922878Major Depressive Disorder
Alto Neuroscience
Phase 2
321
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-06-08
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
California, Colorado, Illinois, Indiana, Massachusetts, Minnesota, Nevada, New York
2023-06-07
Recruiting
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
NCT05948865Cancer, Cancer, Lung
Conjupro Biotherapeutics, Inc.
Phase 1
132
California, Colorado, Florida, New Hampshire, Pennsylvania, Tennessee, Texas, Virginia
2023-06-06
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
Eli Lilly and Company
Phase 3
3,127
Arizona, California, Colorado, Florida, Georgia, Hawaii, Idaho, Kansas
2023-06-05
Active, closed
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05848739Colon Cancer, Metastatic Colon Cancer
Sapience Therapeutics
Phase 1
130
Alabama, California, Colorado, Louisiana, Massachusetts, Michigan, New York, North Carolina
2023-06-05
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
AstraZeneca
Phase 1/2
602
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Active, closed
Pelvic Fixation and Fusion During Multilevel Spinal Surgery
NCT05640908Spinal Fusion, Deformity of Spine
SI-BONE, Inc.
Observational
200
Alabama, Colorado, Michigan, Minnesota, New York, North Carolina, Texas
2023-06-05
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
Nuvation Bio Inc.
Phase 3
365
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-06-05
By invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949Migraine Prophylaxis
AbbVie
Phase 3
650
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-06-05
Active, closed
The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery
NCT05740176Cervical Degenerative Disc Disease
Synergy Spine Solutions
Not applicable
200
Arizona, California, Colorado, Florida, Indiana, Kansas, Louisiana, Michigan
2023-06-01
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
Merck Sharp & Dohme LLC
Phase 2/3
342
California, Colorado, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-05-31
Active, closed
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
NCT05775848Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
ML Bio Solutions, Inc.
Phase 3
112
Arkansas, California, Colorado, Florida, Iowa, Kansas, Maryland, Minnesota
2023-05-31
Active, closed
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis
Apellis Pharmaceuticals, Inc.
Phase 3
100
California, Colorado, Florida, Georgia, Iowa, Michigan, New Jersey, New York
2023-05-29
Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831Locally Advanced Solid Tumor
Tango Therapeutics, Inc.
Phase 1/2
225
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New York, Tennessee
2023-05-26
Active, closed
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Beam Therapeutics Inc.
Phase 1/2
5
California, Colorado, Illinois, Kansas, Massachusetts, Ohio, Oregon, Pennsylvania
2023-05-25
Recruiting
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591Schizophrenia, Bipolar I Disorder
Vanda Pharmaceuticals
Phase 4
100
Arkansas, Colorado, Georgia, Ohio, Washington
2023-05-24
Active, closed
Study of PYX-106 in Solid Tumors
NCT05718557Solid Tumor
Pyxis Oncology, Inc
Phase 1
47
Arizona, California, Colorado, Georgia, Illinois, Massachusetts, Ohio, Rhode Island
2023-05-23
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
Parabilis Medicines, Inc.
Phase 1/2
619
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts
2023-05-23
Active, closed
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
NCT05729568HIV-1 Infection
Gilead Sciences
Phase 2
83
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Missouri, New Mexico
2023-05-15
Active, closed
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
NCT05846516Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
Phase 1
59
California, Colorado, Florida, Michigan, New York, Ohio, Texas, Virginia
2023-05-11
Recruiting
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2
270
California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky, Louisiana
2023-05-09
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Gilead Sciences
Phase 3
654
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana
2023-05-08
Active, closed
Phase III Study of AK112 for NSCLC Patients
NCT06396065Non-Squamous Non-small Cell Lung Cancer
Summit Therapeutics
Phase 3
420
California, Colorado, Florida, Louisiana, Maine, Maryland, Massachusetts, Minnesota
2023-05-04
Active, closed
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
NCT05755711Coronary Artery Disease
Shockwave Medical, Inc.
Observational
399
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas, Louisiana
2023-05-03
Active, closed
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Regeneron Pharmaceuticals
Phase 2
22
Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts
2023-05-03
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394Episodic Migraine
AbbVie
Phase 3
450
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-05-01
Active, closed
Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)
NCT05870124Peripheral Neuralgia, Peripheral Neuropathy, Chronic Pain
Nalu Medical, Inc.
Not applicable
185
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, New Jersey
2023-04-27
Active, closed
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.
Phase 3
143
Alabama, California, Colorado, Florida, Illinois, Iowa, Massachusetts, Minnesota
2023-04-26
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
Phase 3
880
Arizona, Arkansas, California, Colorado, Florida, Hawaii, Idaho, Indiana
2023-04-25
Recruiting
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102Asthma
GlaxoSmithKline
Phase 3
292
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-04-24
Active, closed
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
IDEAYA Biosciences
Phase 1
216
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-04-18
Recruiting
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139Breast Cancer, Solid Tumors, Adult
Eli Lilly and Company
Phase 1/2
880
California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-17
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
Scholar Rock, Inc.
Phase 3
238
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Maryland
2023-04-17
Recruiting
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
NCT05758077Acute Kidney Injury
SeaStar Medical
Not applicable
339
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2023-04-17
Active, closed
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R
Elicio Therapeutics
Phase 1/2
158
Arizona, California, Colorado, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-14
Recruiting
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589Neurotrophic Keratopathy
ReGenTree, LLC
Phase 3
70
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2023-04-11
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-04-11
Recruiting
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
NCT05816382Narcolepsy Type 1
Takeda
Phase 2/3
500
Alabama, California, Colorado, Florida, Georgia, Massachusetts, Michigan, North Carolina
2023-04-05
Active, closed
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05831111Epstein-Barr Virus Infection
ModernaTX, Inc.
Phase 1
482
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-04-05
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
Bayer
Phase 3
985
Arizona, California, Colorado, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2023-04-03
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
Sanofi
Phase 2
999
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2023-04-03
Active, closed
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359Parkinson's Disease
Bial R&D Investments, S.A.
Phase 2
237
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2023-03-31
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma
Iovance Biotherapeutics, Inc.
Phase 3
670
Alabama, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2023-03-30
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana
2023-03-29
Recruiting
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
NCT05440708Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
Phase 1/2
193
Alabama, California, Colorado, District of Columbia, Florida, Maryland, Michigan, Missouri
2023-03-23
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guรฉrin (BCG) in Participants With BCG-naรฏve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
Janssen Research & Development, LLC
Phase 3
1,135
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2023-03-23
Recruiting
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
GV20 Therapeutics
Phase 1/2
365
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Michigan, New York
2023-03-23
Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632Multiple Myeloma
AbbVie
Phase 1
210
Arizona, Arkansas, Colorado, Delaware, Illinois, Indiana, Louisiana, Maryland
2023-03-21
Active, closed
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Enliven Therapeutics
Phase 1
198
Colorado, Florida, Massachusetts, Virginia
2023-03-20
By invitation
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis
Zimmer Biomet
Not applicable
358
Arkansas, Colorado, New Jersey, New York, Ohio, Oregon
2023-03-20
Recruiting
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
NCT05820672Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
Observational
900
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Indiana
2023-03-20
Recruiting
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT05775523Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
Observational
500
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Indiana
2023-03-20
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Alabama, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Maryland
2023-03-17
Recruiting
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
NCT05776069Von Willebrand Diseases
Vega Therapeutics, Inc
Phase 1/2
116
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Texas, Washington
2023-03-16
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Michigan
2023-03-16
Active, closed
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alpine Immune Sciences, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Missouri
2023-03-15
Recruiting
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
NCT05482893Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Phanes Therapeutics
Phase 1/2
258
California, Colorado, Iowa, Kentucky, Massachusetts, North Carolina, Pennsylvania, Texas
2023-03-15
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117Solid Tumor, Advanced Solid Tumor
Pyxis Oncology, Inc
Phase 1
330
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2023-03-14
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-03-09
Recruiting
A Study of BLB-201 RSV Vaccine in Infants and Children
NCT05655182Respiratory Syncytial Virus Infections
Blue Lake Biotechnology Inc.
Phase 1/2
137
California, Colorado, Georgia, Idaho, Kansas, Louisiana, Michigan, Nebraska
2023-03-09
Active, closed
DOR/ISL in HIV-1 Antiretroviral Treatment-naรฏve Participants (MK-8591A-053)
NCT05705349HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
537
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2023-03-08
Active, closed
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399Melanoma
Bristol-Myers Squibb
Phase 3
579
Arizona, Arkansas, California, Colorado, Florida, Maryland, Minnesota, Nebraska
2023-03-06
Recruiting
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971Alpha1-Antitrypsin Deficiency
Takeda
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Iowa
2023-03-06
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
436
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-03-02
Active, closed
A Prospective Cohort Post Market Registry Evaluating Outcomes of Bridge-Enhanced ACL Restoration (BEARยฎ)
NCT05398341Anterior Cruciate Ligament Injuries
Miach Orthopaedics
Observational
300
California, Colorado, Florida, New Jersey, New York, North Carolina, Oregon
2023-02-28
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Phase 3
418
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-27
Active, closed
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 1/2
26
Alabama, California, Colorado, Kansas, Maryland, Massachusetts, Minnesota, Missouri
2023-02-27
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
DBV Technologies
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2023-02-21
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC
Phase 3
12,523
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-15
Active, closed
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
NCT05690386Turner Syndrome
Ascendis Pharma Endocrinology Division A/S
Phase 2
48
California, Colorado, Florida, Georgia, Idaho, Illinois, Massachusetts, Minnesota
2023-02-15
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
Phase 3
160
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2023-02-14
Rows per page Showing 1201–1300 of 2067
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado?page=13

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,067 of those studies with a site in Colorado.

How many clinical trials are recruiting in Colorado?

1,027 of the 2,067 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 29 have not yet opened recruitment, 946 are active but closed to new participants, and 65 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.